Drugs / LY3954068
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06297590 | Aug 2024 → Feb 2027 expected | Alzheimer disease | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3954068 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06297590 ↗ |
| Route | Intrathecal | “Single ascending dose of LY3954068 administered intrathecally (IT)” NCT06297590 ↗ |